Spectrum regaining rights to bladder cancer drug not a positive, The Street says Allergan (AGN) returning the rights to bladder cancer drug apaziquone back to Spectrum Pharmaceuticals (SPPI) is not a positive for Spectrum, contends The Street's Adam Feuerstein. Feuerstein says that Spectrum will need to conduct an additional phase III study of the drug and that the company is going to file for FDA approval based on two, separate studies that each failed to hit their primary endpoints with statistical significance. The Fly notes that Spectrum shares are up about 6.9% to $12.75 in early afternoon trading. Reference Link
News For SPPI;AGN From The Last 14 Days
Check below for free stories on SPPI;AGN the last two weeks.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital.
Subscribe for More Information
